| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 275 | 0.57 | Why? |
| HIV Infections | 10 | 2020 | 11620 | 0.49 | Why? |
| Health Plan Implementation | 1 | 2016 | 571 | 0.45 | Why? |
| Anti-HIV Agents | 4 | 2018 | 2209 | 0.43 | Why? |
| Tenofovir | 3 | 2017 | 449 | 0.39 | Why? |
| Interferon Type I | 5 | 2021 | 2789 | 0.36 | Why? |
| Patient Compliance | 1 | 2016 | 1468 | 0.32 | Why? |
| Critical Pathways | 1 | 2016 | 1587 | 0.31 | Why? |
| Autoantibodies | 3 | 2021 | 2094 | 0.29 | Why? |
| HIV-1 | 2 | 2017 | 3365 | 0.28 | Why? |
| HIV | 2 | 2019 | 1116 | 0.27 | Why? |
| Metabolic Diseases | 1 | 2010 | 505 | 0.27 | Why? |
| Guidelines as Topic | 1 | 2016 | 2844 | 0.26 | Why? |
| Sofosbuvir | 2 | 2019 | 518 | 0.26 | Why? |
| Integrase Inhibitors | 2 | 2018 | 27 | 0.23 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.22 | Why? |
| Macrocyclic Compounds | 1 | 2019 | 78 | 0.19 | Why? |
| HIV-Associated Lipodystrophy Syndrome | 1 | 2018 | 15 | 0.19 | Why? |
| Oxazines | 2 | 2018 | 279 | 0.18 | Why? |
| Genetic Diseases, X-Linked | 1 | 2021 | 237 | 0.18 | Why? |
| Chromosomes, Human, Pair 3 | 1 | 2020 | 195 | 0.18 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Loss of Function Mutation | 1 | 2020 | 244 | 0.18 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2019 | 139 | 0.18 | Why? |
| Receptors, Calcium-Sensing | 1 | 2017 | 18 | 0.18 | Why? |
| Aneurysm, Infected | 1 | 2017 | 36 | 0.18 | Why? |
| Hyperparathyroidism | 1 | 2017 | 38 | 0.18 | Why? |
| Liver Cirrhosis | 2 | 2020 | 1810 | 0.18 | Why? |
| Parathyroid Hormone | 1 | 2017 | 98 | 0.17 | Why? |
| Toll-Like Receptor 7 | 1 | 2021 | 402 | 0.17 | Why? |
| Splenic Infarction | 1 | 2017 | 67 | 0.17 | Why? |
| Pulmonary Gas Exchange | 1 | 2020 | 414 | 0.17 | Why? |
| Piperazines | 2 | 2018 | 445 | 0.17 | Why? |
| Italy | 15 | 2021 | 38444 | 0.17 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Streptococcus agalactiae | 1 | 2017 | 194 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.16 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Methotrexate | 1 | 2020 | 471 | 0.16 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.16 | Why? |
| Radiosurgery | 1 | 2019 | 249 | 0.15 | Why? |
| Carbamates | 1 | 2019 | 485 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| Hospital Mortality | 5 | 2021 | 22087 | 0.14 | Why? |
| Delphi Technique | 1 | 2019 | 1257 | 0.14 | Why? |
| Pyridones | 2 | 2018 | 738 | 0.14 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.13 | Why? |
| Multimorbidity | 1 | 2019 | 703 | 0.13 | Why? |
| Liver Function Tests | 1 | 2020 | 1325 | 0.13 | Why? |
| Endocarditis, Bacterial | 1 | 2017 | 344 | 0.12 | Why? |
| Continuous Positive Airway Pressure | 1 | 2021 | 1187 | 0.11 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.11 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.11 | Why? |
| ABO Blood-Group System | 1 | 2020 | 995 | 0.11 | Why? |
| Physician's Role | 1 | 2020 | 853 | 0.11 | Why? |
| Robotic Surgical Procedures | 1 | 2019 | 787 | 0.11 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.11 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.11 | Why? |
| Sulfonamides | 1 | 2019 | 1294 | 0.10 | Why? |
| Delirium | 1 | 2020 | 1061 | 0.10 | Why? |
| Hepatitis C, Chronic | 1 | 2019 | 973 | 0.10 | Why? |
| Hepacivirus | 1 | 2019 | 1509 | 0.10 | Why? |
| Anti-Retroviral Agents | 1 | 2018 | 1099 | 0.10 | Why? |
| Male | 26 | 2021 | 367725 | 0.10 | Why? |
| Carcinoma, Hepatocellular | 1 | 2019 | 1222 | 0.10 | Why? |
| Genetic Loci | 2 | 2020 | 439 | 0.09 | Why? |
| Antimalarials | 1 | 2021 | 2505 | 0.09 | Why? |
| Risk Factors | 10 | 2021 | 71621 | 0.09 | Why? |
| Genetic Predisposition to Disease | 2 | 2020 | 4027 | 0.09 | Why? |
| Humans | 37 | 2021 | 930598 | 0.09 | Why? |
| Patient Care Management | 1 | 2020 | 1514 | 0.09 | Why? |
| Prone Position | 1 | 2020 | 1861 | 0.09 | Why? |
| Thrombophilia | 1 | 2021 | 1935 | 0.09 | Why? |
| Frailty | 1 | 2020 | 1432 | 0.09 | Why? |
| Proportional Hazards Models | 1 | 2021 | 6543 | 0.09 | Why? |
| Female | 24 | 2021 | 380317 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Liver Neoplasms | 1 | 2019 | 1666 | 0.08 | Why? |
| Aged | 17 | 2021 | 215776 | 0.08 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2020 | 3607 | 0.08 | Why? |
| Adult | 16 | 2021 | 244371 | 0.08 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.08 | Why? |
| Antiviral Agents | 7 | 2021 | 41703 | 0.08 | Why? |
| Pneumonia, Viral | 11 | 2021 | 243684 | 0.08 | Why? |
| Social Determinants of Health | 1 | 2018 | 1757 | 0.08 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.08 | Why? |
| Cohort Studies | 6 | 2020 | 36005 | 0.08 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Alleles | 2 | 2021 | 1557 | 0.07 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.07 | Why? |
| Syndrome | 1 | 2010 | 1310 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Machine Learning | 1 | 2020 | 4395 | 0.07 | Why? |
| CD4 Lymphocyte Count | 2 | 2020 | 1517 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.06 | Why? |
| Hydroxychloroquine | 3 | 2021 | 12447 | 0.06 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.06 | Why? |
| Treatment Outcome | 8 | 2021 | 51732 | 0.06 | Why? |
| Liver Diseases | 1 | 2017 | 2698 | 0.06 | Why? |
| Retrospective Studies | 7 | 2021 | 105322 | 0.06 | Why? |
| Penetrance | 1 | 2021 | 121 | 0.06 | Why? |
| Cluster Analysis | 2 | 2021 | 3001 | 0.06 | Why? |
| Lung Neoplasms | 1 | 2019 | 3228 | 0.06 | Why? |
| Case-Control Studies | 4 | 2021 | 17671 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
| Feasibility Studies | 2 | 2021 | 3467 | 0.05 | Why? |
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2021 | 92 | 0.05 | Why? |
| Drug Therapy, Combination | 3 | 2021 | 7268 | 0.05 | Why? |
| Validation Studies as Topic | 1 | 2020 | 121 | 0.05 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.05 | Why? |
| Chemokine CXCL9 | 1 | 2021 | 154 | 0.05 | Why? |
| Betacoronavirus | 10 | 2020 | 204454 | 0.05 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2020 | 196 | 0.05 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.05 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.05 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 120 | 0.05 | Why? |
| Calgranulin B | 1 | 2021 | 144 | 0.05 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.05 | Why? |
| Interferon Regulatory Factor-7 | 1 | 2020 | 234 | 0.05 | Why? |
| Pedigree | 1 | 2021 | 502 | 0.05 | Why? |
| Interleukin-15 | 1 | 2021 | 169 | 0.05 | Why? |
| Breath Holding | 1 | 2019 | 13 | 0.05 | Why? |
| Lipocalin-2 | 1 | 2021 | 156 | 0.05 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2021 | 211 | 0.05 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 229 | 0.05 | Why? |
| Diagnostic Equipment | 1 | 2019 | 41 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Retreatment | 1 | 2019 | 186 | 0.05 | Why? |
| Multigene Family | 1 | 2020 | 377 | 0.05 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.05 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.05 | Why? |
| Interleukin-2 | 1 | 2021 | 443 | 0.05 | Why? |
| Lactoferrin | 1 | 2021 | 208 | 0.05 | Why? |
| Hypertension | 2 | 2019 | 8895 | 0.05 | Why? |
| Phantoms, Imaging | 1 | 2019 | 146 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Cross Infection | 1 | 2021 | 8675 | 0.05 | Why? |
| Chemokine CCL2 | 1 | 2021 | 389 | 0.05 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.05 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.04 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.04 | Why? |
| Receptor, Interferon alpha-beta | 1 | 2020 | 610 | 0.04 | Why? |
| Infant | 4 | 2021 | 30274 | 0.04 | Why? |
| Odds Ratio | 1 | 2010 | 5861 | 0.04 | Why? |
| Maximum Tolerated Dose | 1 | 2017 | 65 | 0.04 | Why? |
| Toll-Like Receptor 3 | 1 | 2020 | 391 | 0.04 | Why? |
| Splenectomy | 1 | 2017 | 85 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2019 | 378 | 0.04 | Why? |
| Survival Analysis | 2 | 2021 | 7592 | 0.04 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.04 | Why? |
| Compassionate Use Trials | 1 | 2021 | 632 | 0.04 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.04 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.04 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.04 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.04 | Why? |
| Viral Load | 1 | 2016 | 15850 | 0.04 | Why? |
| Respiratory Mechanics | 1 | 2020 | 585 | 0.04 | Why? |
| Blotting, Western | 1 | 2017 | 863 | 0.04 | Why? |
| Comorbidity | 4 | 2020 | 34796 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2018 | 10697 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2020 | 1262 | 0.03 | Why? |
| Intensive Care Units | 4 | 2021 | 29594 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Interleukin-10 | 1 | 2021 | 1409 | 0.03 | Why? |
| Lipid Metabolism | 1 | 2018 | 572 | 0.03 | Why? |
| NF-kappa B | 1 | 2021 | 1301 | 0.03 | Why? |
| Mortality | 2 | 2020 | 7132 | 0.03 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.03 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2021 | 861 | 0.03 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Young Adult | 5 | 2021 | 93724 | 0.03 | Why? |
| Drug Resistance, Viral | 1 | 2019 | 1083 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2021 | 27595 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Geriatric Assessment | 1 | 2020 | 1372 | 0.03 | Why? |
| Child | 4 | 2021 | 70012 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2019 | 1425 | 0.03 | Why? |
| Asymptomatic Infections | 2 | 2020 | 7218 | 0.03 | Why? |
| Interferon-gamma | 1 | 2021 | 2711 | 0.03 | Why? |
| Enzyme Inhibitors | 1 | 2021 | 1881 | 0.03 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2021 | 5440 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2021 | 3788 | 0.02 | Why? |
| Safety | 1 | 2017 | 1583 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2019 | 53120 | 0.02 | Why? |
| Uncertainty | 1 | 2019 | 1888 | 0.02 | Why? |
| Noninvasive Ventilation | 1 | 2021 | 2329 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2021 | 3629 | 0.02 | Why? |
| Age Factors | 2 | 2020 | 21039 | 0.02 | Why? |
| Anti-Bacterial Agents | 2 | 2021 | 10083 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.02 | Why? |
| Azithromycin | 1 | 2021 | 3943 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Cell Line | 1 | 2020 | 12040 | 0.02 | Why? |
| Immunologic Factors | 1 | 2021 | 4206 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Sepsis | 1 | 2021 | 3517 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.02 | Why? |
| Ritonavir | 1 | 2018 | 4212 | 0.02 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.01 | Why? |
| Protease Inhibitors | 1 | 2018 | 3630 | 0.01 | Why? |
| Molecular Docking Simulation | 1 | 2017 | 6902 | 0.01 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3832 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Viral Nonstructural Proteins | 1 | 2019 | 4810 | 0.01 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2019 | 8207 | 0.01 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2019 | 25144 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2019 | 43792 | 0.01 | Why? |
| Animals | 1 | 2020 | 78931 | 0.01 | Why? |